REM sleep behavior disorder (RBD) is a common parasomnia disorder affecting between 1 and 7 % of community-dwelling adults, most frequently older adults. RBD is characterized by nocturnal complex motor behavior and polysomnographic REM sleep without atonia. RBD is strongly associated with synucleinopathy neurodegeneration. The approach to RBD management is currently twofold: symptomatic treatment to prevent injury and prognostic counseling and longitudinal follow-up surveillance for phenoconversion toward overt neurodegenerative disorders. The focus of this review is symptomatic treatment for injury prevention. Injury occurs in up to 55 % of patients prior to treatment, even when most behaviors seem to be infrequent or minor, so patients with RBD should be treated promptly following diagnosis to prevent injury risk. A sound evidence basis for symptomatic treatment of RBD remains lacking, and randomized controlled treatment trials are needed. Traditional therapeutic mainstays with relatively robust retrospective case series level evidence include melatonin and clonazepam, which appear to be equally effective, although melatonin is more tolerable. Melatonin also has one small randomized controlled crossover trial supporting its use for RBD treatment. Melatonin dosed 3–12 mg at bedtime should be considered as the first-line therapy, followed by clonazepam 0.25–2.0 mg at bedtime if initial melatonin is judged ineffective or intolerable. However, neither agent is likely to completely stop dream enactment behaviors, so choosing a moderate target dosage of melatonin 6 mg or clonazepam 0.5 mg, or the highest tolerable dosage that reduces attack frequency and avoids adverse effects from overtreatment, is currently the most reasonable strategy. Alternative second- and third-line therapies with anecdotal efficacy include temazepam, lorazepam, zolpidem, zopiclone, pramipexole, donepezil, ramelteon, agomelatine, cannabinoids, and sodium oxybate. A novel non-pharmacological approach is a bed alarm system, although this may be most useful in patients who also report sleep walking or a history of leaving their bed during dream enactment episodes. The benefit of hypnosis, especially in those with psychiatric RBD, also requires further study. RBD is an attractive target for future neuroprotective treatment trials to prevent evolution of overt parkinsonism or memory decline, but currently, there are no known effective treatments and future trials will be necessary to determine if RBD is an actionable time point in the evolution of overt synucleinopathy.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Schenck CH et al. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep. 1986;9(2):293–308.
Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep. 2002;25(2):120–38. This landmark article describes clinical and therapeutic approaches in a large series of REM sleep behavior disorder by the sleep neurology pioneers, Schenck and Mahowald, who discovered and initially described the condition in humans at the Minnesota Regional Sleep Disorders Center based at Hennepin County Medical Center Sleep in Minneapolis.
International classification of sleep disorders. 3rd ed. Westchester, IL: American Academy of Sleep Medicine 2014.
Boeve BF. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci. 2010;1184:15–54. This encyclopedic review article comprehensively reviews clinical, pathophysiologic, pathologic, imaging, and treatment aspects of REM sleep behavior disorder, including alternative approaches to treatment in refractory cases such as the use of sodium oxybate.
Chiu HF et al. Sleep-related injury in the elderly—an epidemiological study in Hong Kong. Sleep. 2000;23(4):513–7.
Ohayon MM, Schenck CH. Violent behavior during sleep: prevalence, comorbidity and consequences. Sleep Med. 2010;11(9):941–6.
Boeve BF et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med. 2011;12(5):445–53.
Boot BP et al. Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study. Ann Neurol. 2012;71(1):49–56.
Boeve BF et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013;14(8):754–62.
Iranzo A et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 2013;12(5):443–53.
Schenck CH et al. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med. 2013;14(8):744–8.
Iranzo A et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One. 2014;9(2):e89741.
Postuma RB et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009;72(15):1296–300.
Iranzo A et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol. 2010;9(11):1070–7.
Schenck CH et al. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med. 2013;14(8):795–806. This consensus position paper of the International RBD Study Group proposes future approaches to symptomatic and neuroprotective clinical trials for REM sleep behavior disorder.
Hancock KL et al. Quantitative analyses of REM sleep without atonia in children and adolescents with REM sleep behavior disorder. Minn Med. 2014;97(5):43.
Lloyd R et al. Characteristics of REM sleep behavior disorder in childhood. J Clin Sleep Med. 2012;8(2):127–31.
Dauvilliers Y et al. Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia in narcolepsy. Sleep Med. 2013;14(8):775–81.
St Louis EK et al. Lesional REM sleep behavior disorder localizes to the dorsomedial pons. Neurology. 2014;83(20):1871–3.
McCarter SJ et al. Neuroimaging-evident lesional pathology associated with REM sleep behavior disorder. Sleep Med. 2015;16(12):1502–10.
Iranzo A et al. Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann Neurol. 2006;59(1):178–81.
Cornelius JR et al. Sleep manifestations of voltage-gated potassium channel complex autoimmunity. Arch Neurol. 2011;68(6):733–8.
Lee K, et al. The Prevalence and Characteristics of REM Sleep without Atonia (RSWA) in Patients Taking Antidepressants. J Clin Sleep Med. 2015.
Postuma RB et al. Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal? Sleep. 2013;36(11):1579–85.
McCarter SJ et al. Antidepressants Increase REM Sleep Muscle Tone in Patients with and without REM Sleep Behavior Disorder. Sleep. 2015;38(6):907–17.
Feinstein M SR, Sandness DJ, Timm PC, Lipford M, Tippmann-Peikert M, Junna M, Silber MH, Boeve BF, St. Louis EK. Counseling of the patient with idiopathic REM sleep behavior disorder and incidental polysomnographic REM sleep without atonia: a retrospective analysis. Sleep. 2016;39(Suppl (abstract)):A239.
Arnaldi D AE, St. Louis EK, Postuma RB, Arnulf I. Idiopathic REM sleep behavior disorder and neurodegenerative risk: to tell or not to tell the patient, and how to minimize the risk? (Unpublished observations, manuscript).
Boeve BF et al. REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology. 1998;51(2):363–70.
Comella CL et al. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson’s disease. Neurology. 1998;51(2):526–9.
Olson EJ et al. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain. 2000;123(Pt 2):331–9.
McCarter SJ et al. Factors associated with injury in REM sleep behavior disorder. Sleep Med. 2014;15(11):1332–8. This paper reviewed the frequency of injury in untreated REM sleep behavior disorder, finding that 55% of idiopathic RBD patients reported injury prior to treatment, 11.3% with serious injuries such as subdural hematomas. While not discussing treatment per se, the alarming frequency of injury suggest that treatment to prevent injury should be a major priority in the care of RBD patients.
Chokroverty S. Editorial: “Injurious RBD and DEB frequency: are they related?”. Sleep Med. 2014;15(11):1287.
Schenck CH et al. Symposium: Normal and abnormal REM sleep regulation: REM sleep behaviour disorder: an update on a series of 96 patients and a review of the world literature. J Sleep Res. 1993;2(4):224–31.
McCarter SJ et al. REM sleep behavior disorder and REM sleep without atonia as an early manifestation of degenerative neurological disease. Curr Neurol Neurosci Rep. 2012;12(2):182–92.
Boeve BF et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain. 2007;130(Pt 11):2770–88.
Anderson KN, Shneerson JM. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med. 2009;5(3):235–9. This article assessed alternative treatments to clonazepam used in open clinical experience in REM sleep behavior disorder management, especially finding zopiclone as a suitable alternative in some patients.
Brooks PL, Peever JH. Impaired GABA and glycine transmission triggers cardinal features of rapid eye movement sleep behavior disorder in mice. J Neurosci. 2011;31(19):7111–21.
Lapierre O, Montplaisir J. Polysomnographic features of REM sleep behavior disorder: development of a scoring method. Neurology. 1992;42(7):1371–4.
Ferri R et al. An observational clinical and video-polysomnographic study of the effects of clonazepam in REM sleep behavior disorder. Sleep Med. 2013;14(1):24–9.
Li SX et al. A prospective, naturalistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behavior disorder. Sleep Med. 2016;21:114–20. This excellent new open study of clonazepam in 39 RBD patients found that an effective Treatment response, as defined by a complete elimination of sleep-related injuries and potentially injurious behaviors to self and/or to bed partner, was reported in 66.7% of the patients. Interestingly, there was no apparent effect on polysomnographic REM atonia, and decreased nightmarish dream content seemed most associated with efficacy.Patients with earlier onset RBD symptoms or history of co-morbid sleep apnea showed less beneficial treatment responses to clonazepam.
Bonakis A et al. REM sleep behaviour disorder (RBD) and its associations in young patients. Sleep Med. 2009;10(6):641–5.
Schenck CH, Mahowald MW. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med. 1996;100(3):333–7. This large case series reported the efficacy and long term tolerability of clonazepam for treatment of injurious parasomnias including 52 patients with REM sleep behavior disorder, finding effective control in the majority of patients.
McCarter SJ et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med. 2013;14(3):237–42. This case series of 45 REM sleep behavior disorder patients remains the largest comparative study between melatonin and clonazepam to date, finding through survey based patient reported outcomes that both treatments were approximately equally effective at reducing RBD frequency and severity, while melatonin was better tolerated.
Aurora RN et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85–95. This article comprehensively assessed available literature through 2010 concerning REM sleep behavior disorder treatment, and as the present review, concentrated on clonazepam and melatonin but also examining then published alternative., and also provided evidence level ratings for various treatments, reporting Level A evidence for safety measures, Level B for clonazepam and melatonin, and Level C for other alternatives such as pramipexole, zopiclone, benzodiazepines other than clonazepam, Yi-Gan San, desipramine, clozapine, carbamazepine, and sodium oxybate.
Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19(4):591–6. This small randomized crossover trial showed efficacy of melatonin and its apparent biological impact on improving REM sleep atonia in 8 patients with REM sleep behavior disorder.
Kunz D, Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Disord. 1999;14(3):507–11.
Takeuchi N et al. Melatonin therapy for REM sleep behavior disorder. Psychiatry Clin Neurosci. 2001;55(3):267–9.
Boeve BF et al. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003;4(4):281–4. This case series showed practical clinical utility for melatonin therapy for REM sleep behavior disorder.
Attenburrow ME et al. Low dose melatonin improves sleep in healthy middle-aged subjects. Psychopharmacology (Berl). 1996;126(2):179–81.
Zhdanova IV et al. Effects of low oral doses of melatonin, given 2–4 hours before habitual bedtime, on sleep in normal young humans. Sleep. 1996;19(5):423–31.
Kunz D et al. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. J Clin Endocrinol Metab. 2004;89(1):128–34.
Nomura T et al. Use of ramelteon for the treatment of secondary REM sleep behavior disorder. Intern Med. 2013;52(18):2123–6.
Esaki Y, et al. An Open-Labeled Trial of Ramelteon in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. J Clin Sleep Med. 2016.
St. Louis EK, McCarter SJ, Boeve BF. Ramelteon for idiopathic REM sleep behavior disorder: implications for pathophysiology and future treatment trials. JCSM. 2016;12(5):643–5.
Bonakis A et al. Agomelatine may improve REM sleep behavior disorder symptoms. J Clin Psychopharmacol. 2012;32(5):732–4.
Zucconi M, et al. Agomelatine in idiopathic REM sleep behavior disorder. 37. 2014;Supplement:A212.
Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002;2:CD001520.
Takeda Pharmaceuticals. Rozerem prescribing information. Accessed July 27, 2016. Available from: http://general.takedapharm.com/content/file.aspx?applicationcode=2bcc07ca-d9c0-4704-9a28-963127115641&filetypecode=rozerempi&cacheRandomizer=cf7c4908-1b22-4b10-a7b0-df26e88fb0a1.
Verhave PS et al. REM sleep behavior disorder in the marmoset MPTP model of early Parkinson disease. Sleep. 2011;34(8):1119–25.
Fantini ML et al. The effects of pramipexole in REM sleep behavior disorder. Neurology. 2003;61(10):1418–20.
Schmidt MH et al. Use of pramipexole in REM sleep behavior disorder: results from a case series. Sleep Med. 2006;7(5):418–23.
Sasai T et al. Factors associated with the effect of pramipexole on symptoms of idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord. 2013;19(2):153–7.
Kumru H et al. Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease. Sleep. 2008;31(10):1418–21.
Shiromani PJ et al. Acetylcholine and the regulation of REM sleep: basic mechanisms and clinical implications for affective illness and narcolepsy. Annu Rev Pharmacol Toxicol. 1987;27:137–56.
Jones BE. The organization of central cholinergic systems and their functional importance in sleep-waking states. Prog Brain Res. 1993;98:61–71.
Holsboer-Trachsler E et al. Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man. Neuropsychopharmacology. 1993;8(1):87–92.
Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology. 2000;55(6):870–1.
Di Giacopo R et al. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson’s disease. Mov Disord. 2012;27(4):559–61.
Brunetti V et al. Rivastigmine for refractory REM behavior disorder in mild cognitive impairment. Curr Alzheimer Res. 2014;11(3):267–73.
Carlander B, Touchon J, Ondze B, Billard M. REM sleep behavior disorder induced by cholinergic treatment in Alzheimer’s disease. J Sleep Res. 1996;5 suppl 1:28.
Shinno H et al. Successful treatment with Yi-Gan San for rapid eye movement sleep behavior disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(7):1749–51.
Shneerson JM. Successful treatment of REM sleep behavior disorder with sodium oxybate. Clin Neuropharmacol. 2009;32(3):158–9.
Howell MJ et al. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med. 2011;7(6):639–44A. This report in four medication refractory REM sleep behavior disorder patients showed evidence for decreased injury and symptoms, offering a novel approach to therapy without adverse effects.
Dumitrascu O et al. Parasomnia overlap disorder: a distinct pathophysiologic entity or a variant of rapid eye movement sleep behavior disorder? A case series. Sleep Med. 2013;14(11):1217–20.
Howell MJ, Schenck CH. Rapid eye movement sleep behavior disorder and neurodegenerative disease. JAMA Neurol. 2015;72(6):707–12.
Hurwitz TD et al. A retrospective outcome study and review of hypnosis as treatment of adults with sleepwalking and sleep terror. J Nerv Ment Dis. 1991;179(4):228–33.
Hauri PJ et al. The treatment of parasomnias with hypnosis: a 5-year follow-up study. J Clin Sleep Med. 2007;3(4):369–73.
Larsen V SD, Richardson J, Boeve BF, Silber MH, St. Louis EK. Clinical characteristics and treatment outcomes of patients treated with hypnosis for parasomnias. Sleep. 2016;39(Suppl (abstract)):A237.
Chagas MH et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther. 2014;39(5):564–6.
The project described was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number 1 UL1 RR024150-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Conflict of Interest
Youngsin Jung declares no conflict of interest
Erik K. St Louis reports personal fees from Inspire, Inc., and Wiley-Blackwell, outside the submitted work.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
This article is part of the Topical Collection on Sleep Disorders
About this article
Cite this article
Jung, Y., St. Louis, E.K. Treatment of REM Sleep Behavior Disorder. Curr Treat Options Neurol 18, 50 (2016). https://doi.org/10.1007/s11940-016-0433-2
- REM sleep behavior disorder
- Acetylcholinesterase inhibitor
- Adverse effects
- Bed alarm